Featured Research

from universities, journals, and other organizations

Plant Compound Blocks Action Of Cancer Genes

August 31, 2000
Howard Hughes Medical Institute
A plant compound that produces severe neural defects in developing embryos can block the action of mutated genes that produce basal cell skin carcinomas, the most common form of human cancer.

August 31, 2000 -— A plant compound that produces severe neural defects in developing embryos can block the action of mutated genes that produce basal cell skin carcinomas, the most common form of human cancer.

Related Articles

According to researchers at the Howard Hughes Medical Institute (HHMI) at The Johns Hopkins University School of Medicine, the studies in mouse cells suggest that the drug may be used to treat a number of cancers, including medulloblastomas in the brain and rhabdomyosarcomas in muscle. The finding also spotlights the promise of mechanism-based treatment approaches that target specific signaling pathways that are critical to a particular cancer. Conventional chemotherapy, in sharp contrast, kills cancer cells by attacking all proliferating cells—killing healthy tissue in the process.

In an article in the August 31, 2000, issue of the journal Nature, HHMI investigator Philip A. Beachy and his colleagues reported that the plant compound cyclopamine interferes with the action of the protein encoded by the gene, Smoothened. When Smoothened or its regulator Patched are mutated in skin cells, the cells grow without their normal constraints, and cancer can arise. Smoothened and Patched play a role in sensing the signal produced by Hedgehog, a critical protein in embryonic development.

Beachy's co-authors on the Nature article included Jussi Taipale and colleagues at Hopkins, and HHMI investigator Matthew P. Scott and his colleagues at Stanford University School of Medicine.

"It had long been known that animals that consumed plants containing cyclopamine suffered severe neural birth defects, including malformations that produced a single cyclopic eye," said Beachy. "And when we knocked out the mouse counterpart of the hedgehog gene, Sonic hedgehog, we saw an effect very much like that produced in animals by cyclopamine. So, that really rang a bell for us."

After initial experiments indicated that cyclopamine did not directly affect the Hedgehog protein, the scientists turned their attention to the two cellular targets that receive signals from Hedgehog—proteins produced by the genes Smoothened and Patched. While the Smoothened protein switches on cell division, the Patched protein acts as a cellular "brake," or tumor suppressor. Previous studies had shown that Hedgehog switches on cell division by binding to Patched, turning off its normal braking function, and allowing Smoothened to activate cell proliferation.

The scientists’ experiments ruled out that cyclopamine might thwart proliferation by activating the Patched protein. They found instead that when they deleted the Patched gene from mouse cells, cyclopamine could still turn off cell division. "Thus, we’d eliminated two red herrings—that cyclopamine affected either Hedgehog or Patched," said Beachy.

To test whether Smoothened was cyclopamine’s target, the scientists first produced mouse cells that expressed high levels of the Smoothened protein. Cyclopamine still suppressed activation of those cells. To investigate the limits of cyclopamine’s suppression, the scientists next tested the drug’s effects on mouse cells that possessed mutant activated forms of the Smoothened protein that were freed from control by Patched.

These mutant Smoothened-activated cells, the scientists found, proliferated regardless of cyclopamine treatment. Importantly, however, the mutant cells were suppressed by a more potent, synthetic form of cyclopamine.

"All these findings lead us to believe that Smoothened is the target of cyclopamine action, concluded Beachy. "And now that we have evidence that Smoothened is the target, we can further explore whether the interaction is direct or indirect."

Also, said Beachy, further experiments will test the effects of cyclopamine on tumors grown in mice that arise in cells lacking the Patched tumor suppressor.

Beachy emphasized that cyclopamine’s potential as a cancer therapy also illustrates the enormous potential of mechanism-based cancer therapies. "There are many efforts being made in universities and pharmaceutical companies to identify critical signaling pathways in tumors that could represent specific therapeutic targets," he said. "And these efforts will certainly lead to treatments far more effective and less toxic than standard chemotherapeutic agents, which are basically cell poisons."

Story Source:

The above story is based on materials provided by Howard Hughes Medical Institute. Note: Materials may be edited for content and length.

Cite This Page:

Howard Hughes Medical Institute. "Plant Compound Blocks Action Of Cancer Genes." ScienceDaily. ScienceDaily, 31 August 2000. <www.sciencedaily.com/releases/2000/08/000831074947.htm>.
Howard Hughes Medical Institute. (2000, August 31). Plant Compound Blocks Action Of Cancer Genes. ScienceDaily. Retrieved March 30, 2015 from www.sciencedaily.com/releases/2000/08/000831074947.htm
Howard Hughes Medical Institute. "Plant Compound Blocks Action Of Cancer Genes." ScienceDaily. www.sciencedaily.com/releases/2000/08/000831074947.htm (accessed March 30, 2015).

Share This

More From ScienceDaily

More Health & Medicine News

Monday, March 30, 2015

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins